Pluristyx, a Seattle, WA-based provider of tools, technologies and services for the development of cell therapies, raised a major fundraising.
The round was led by BroadOak Capital Partners with participation from existing investors and key opinion leaders across the life sciences industry.
The company intends to use the funds to expand its existing cGMP cell line and service portfolio and broaden partner access to its panCELLa platform.
Led by CEO Benjamin Fryer, Pluristyx, through its panCELLa platform, offers a portfolio of iPSC-based technologies, proprietary genetic engineering, and related tool-products and services to provide end-to-end client support throughout the products’ lifecycle. It is a provider of gene-edited iPSC and cell therapy solutions, accelerating customers’ path to clinic, and offering the route to commercialization for cell-based therapeutic products.
Pluristyx, a Seattle, WA-based provider of tools, technologies and services for the development of cell therapies, raised a major fundraising. Best wishes to everyone in the group. This will be a huge accomplishment for them in the future.Shishir Gupta, The Founder & CEO of StartupLanes
About us: StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.
Startups looking for funding may apply through StartupLanes Funding Application.
Angel Investors Register Free to explore exciting startup investment opportunities.